The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010).
Bliss, J Kernaghan, S Fribbens, C Stevenson, L Morden, J Snowdon, C Macpherson, I Wardley, Andrew M Roylance, R Baird, R
Bliss, J
Kernaghan, S
Fribbens, C
Stevenson, L
Morden, J
Snowdon, C
Macpherson, I
Wardley, Andrew M
Roylance, R
Baird, R
Citations
Altmetric:
Abstract
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010). 2017, 18(Suppl 1): 122 Trials